Bioprocess Development Biologicals, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany.
Institute of Functional Interfaces, Karlsruhe Institute of Technology, Karlsruhe, Germany.
Biotechnol Bioeng. 2024 Oct;121(10):3181-3195. doi: 10.1002/bit.28767. Epub 2024 Jun 10.
Ensuring the quality and safety of biopharmaceutical products requires the effective separation of monoclonal antibodies (mAbs) from host cell proteins (HCPs). A major challenge in this field is the enzymatic hydrolysis of polysorbates (PS) in drug products. This study addresses this issue by investigating the removal of polysorbate-degrading HCPs during the polishing steps of downstream purification, an area where knowledge about individual HCP behavior is still limited. We investigated the separation of different mAb formats from four individual polysorbate degrading hydrolases (CES1F, CES2C, LPLA2, and PAF-AH) using cation exchange (CEX) and mixed-mode chromatography (MMC) polishing steps. Our research identified a key challenge: The similar elution behavior of mAbs and HCPs during chromatographic separation. To investigate this phenomenon, we performed high-throughput binding screenings for recombinant polysorbate degrading hydrolases and representative mAb candidates on CEX and MMC chromatography resins. We then employed a three-step strategy that also served as a scale-up process, optimizing separation conditions and leading to the successful removal of specific HCPs while maintaining high mAb recovery rates (>96%). This strategy involved the use of surface response models and miniature columns for screening, followed by validation on larger columns using a chromatography system. Our results highlight the critical role of the inherent properties of mAbs for successful separation from HCPs. These results underscore the need to tailor the purification process to leverage the slight differences in binding behavior and elution profiles between mAbs and specific HCPs. This approach lays the foundation for developing more effective strategies for overcoming the challenge of enzymatic polysorbate degradation, paving the way for improved quality and safety in biopharmaceutical products.
确保生物制药产品的质量和安全性需要有效地将单克隆抗体 (mAbs) 与宿主细胞蛋白 (HCPs) 分离。在这个领域中,一个主要的挑战是药物产品中聚山梨酯 (PS) 的酶水解。本研究通过研究在下游纯化的抛光步骤中去除聚山梨酯降解 HCPs 来解决这个问题,在这个领域,关于个别 HCP 行为的知识仍然有限。我们研究了使用阳离子交换 (CEX) 和混合模式色谱 (MMC) 抛光步骤从四种不同的聚山梨酯降解水解酶 (CES1F、CES2C、LPLA2 和 PAF-AH) 中分离不同的 mAb 形式。我们的研究确定了一个关键挑战:在色谱分离过程中 mAbs 和 HCPs 的洗脱行为相似。为了研究这种现象,我们在 CEX 和 MMC 色谱树脂上对重组聚山梨酯降解水解酶和代表性 mAb 候选物进行了高通量结合筛选。然后,我们采用了三步策略,该策略还可作为放大过程,优化分离条件,成功去除特定的 HCPs,同时保持高 mAb 回收率 (>96%)。该策略涉及使用表面响应模型和微型柱进行筛选,然后在更大的柱上使用色谱系统进行验证。我们的结果强调了 mAbs 的固有特性对于成功与 HCPs 分离的关键作用。这些结果强调了需要根据特定 HCP 与 mAbs 之间的结合行为和洗脱曲线的细微差异来定制纯化工艺。这种方法为开发更有效的策略克服酶解聚山梨酯降解的挑战奠定了基础,为提高生物制药产品的质量和安全性铺平了道路。